Replies to post #23504 on Humanigen Inc (fka HGENQ)

[Knuckle Sandwich]

The Lenzilumab Arm is the only Arm selected for treating Severe COVID-19 infection. There other 3 Arms are Prophylaxis, Post-Exposure Prophylaxis and Moderate. The study estimated completion is 12/2021 but I assume results will be provided as each individual arm is completed? I think the fact that Lenz was singled out as the therapeutic for Severe shows allot of confidence in what the potential is especially with a highly vulnerable patient population.

Experimental: Severe COVID-19 infection
This study arm (arm 4) is evaluating the effect of Lenzilumab on the treatment of COVID-19 infection in cancer patients with severe COVID-19 infection.

Participants in this study arm are randomly allocated (by chance) to one of two groups. One group will receive intravenous Lenzilumab over 24 hours while the other group will receive placebo intravenously over 24 hours.

Participants will be followed for 60 days to assess effectiveness and safety.

https://clinicaltrials.gov/ct2/show/NCT04534725?id=NCT04351152+OR+NCT04314843+OR+NCT03374943+OR+NCT04534725+OR+NCT04583969&draw=2&rank=2&load=cart